KeyBank National Association’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.93M Sell
9,934
-468
-4% -$207K 0.02% 316
2026
Q1
$4.64M Buy
10,402
+272
+3% +$127K 0.02% 313
2025
Q4
$4.59M Buy
10,130
+91
+0.9% +$39.2K 0.02% 308
2025
Q3
$3.93M Sell
10,039
-639
-6% -$267K 0.01% 328
2025
Q2
$4.75M Sell
10,678
-1,523
-12% -$702K 0.02% 303
2025
Q1
$5.92M Buy
12,201
+83
+0.7% +$38.7K 0.02% 272
2024
Q4
$4.88M Buy
12,118
+147
+1% +$68.1K 0.02% 293
2024
Q3
$5.57M Sell
11,971
-1,694
-12% -$814K 0.02% 277
2024
Q2
$6.41M Buy
13,665
+652
+5% +$283K 0.03% 256
2024
Q1
$5.44M Sell
13,013
-781
-6% -$330K 0.02% 276
2023
Q4
$5.61M Sell
13,794
-814
-6% -$301K 0.02% 266
2023
Q3
$5.08M Sell
14,608
-25
-0.2% -$8.74K 0.02% 262
2023
Q2
$5.15M Sell
14,633
-95
-0.6% -$32K 0.02% 267
2023
Q1
$4.64M Sell
14,728
-793
-5% -$238K 0.02% 272
2022
Q4
$4.48M Sell
15,521
-691
-4% -$211K 0.02% 276
2022
Q3
$4.69M Sell
16,212
-1,237
-7% -$356K 0.02% 256
2022
Q2
$4.92M Sell
17,449
-970
-5% -$260K 0.02% 264
2022
Q1
$4.81M Sell
18,419
-1,350
-7% -$320K 0.02% 276
2021
Q4
$4.34M Sell
19,769
-7,086
-26% -$1.38M 0.02% 292
2021
Q3
$4.87M Sell
26,855
-6,306
-19% -$1.23M 0.02% 268
2021
Q2
$6.69M Sell
33,161
-13,751
-29% -$2.88M 0.03% 241
2021
Q1
$10.1M Sell
46,912
-42,535
-48% -$9.34M 0.05% 210
2020
Q4
$21.1M Sell
89,447
-38,958
-30% -$8.94M 0.1% 149
2020
Q3
$34.9M Sell
128,405
-1,017
-0.8% -$281K 0.19% 109
2020
Q2
$37.6M Buy
129,422
+42,505
+49% +$11.5M 0.22% 102
2020
Q1
$20.7M Buy
86,917
+27,636
+47% +$6.34M 0.14% 127
2019
Q4
$13M Buy
59,281
+57,190
+2,735% +$11.6M 0.07% 180
2019
Q3
$354K Sell
2,091
-230
-10% -$40.7K ﹤0.01% 792
2019
Q2
$426K Sell
2,321
-19
-0.8% -$3.32K ﹤0.01% 783
2019
Q1
$430K Sell
2,340
-6
-0.3% -$1.11K ﹤0.01% 745
2018
Q4
$389K Buy
2,346
+52
+2% +$9.01K ﹤0.01% 716
2018
Q3
$442K Sell
2,294
-429
-16% -$76.4K ﹤0.01% 798
2018
Q2
$463K Buy
2,723
+426
+19% +$66K ﹤0.01% 765
2018
Q1
$374K Buy
2,297
+223
+11% +$36.4K ﹤0.01% 827
2017
Q4
$311K Sell
2,074
-2,440
-54% -$361K ﹤0.01% 884
2017
Q3
$686K Sell
4,514
-73
-2% -$11K ﹤0.01% 689
2017
Q2
$591K Buy
4,587
+232
+5% +$27.9K ﹤0.01% 758
2017
Q1
$476K Sell
4,355
-210
-5% -$18.5K ﹤0.01% 829
2016
Q4
$336K Buy
4,565
+1,382
+43% +$112K ﹤0.01% 935
2016
Q3
$277K Buy
3,183
+167
+6% +$15.8K ﹤0.01% 1006
2016
Q2
$259K Sell
3,016
-143
-5% -$12.4K ﹤0.01% 980
2016
Q1
$251K Sell
3,159
-1,118
-26% -$101K ﹤0.01% 974
2015
Q4
$538K Sell
4,277
-1,903
-31% -$230K ﹤0.01% 753
2015
Q3
$644K Buy
6,180
+901
+17% +$116K ﹤0.01% 705
2015
Q2
$652K Sell
5,279
-3,504
-40% -$442K ﹤0.01% 736
2015
Q1
$1.04M Buy
8,783
+5,503
+168% +$659K 0.01% 624
2014
Q4
$390K Sell
3,280
-61
-2% -$6.87K ﹤0.01% 941
2014
Q3
$375K Sell
3,341
-683
-17% -$65K ﹤0.01% 960
2014
Q2
$381K Sell
4,024
-989
-20% -$69.3K ﹤0.01% 1002
2014
Q1
$355K Sell
5,013
-162
-3% -$12.8K ﹤0.01% 1030
2013
Q4
$385K Sell
5,175
-4,509
-47% -$314K ﹤0.01% 997
2013
Q3
$734K Buy
9,684
+625
+7% +$49.7K 0.01% 748
2013
Q2
$724K Buy
+9,059
New +$667K ﹤0.01% 866

Other funds holding VRTX

KeyBank National Association's VRTX Position: Q2 2026 in Review

KeyBank National Association reduced its Vertex Pharmaceuticals (VRTX) stake by 4.5% in Q2 2026, selling an estimated $207K and leaving 9,934 shares worth $4.93M. The position accounts for 0.02% of the portfolio, ranked #316.

KeyBank National Association first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. The position peaked at $37.6M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • KeyBank National Association held 9,934 shares of Vertex Pharmaceuticals worth $4.93M as of Q2 2026.
  • KeyBank National Association sold 468 Vertex Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Vertex Pharmaceuticals made up 0.02% of KeyBank National Association's portfolio in Q2 2026, its #316 holding.
  • KeyBank National Association first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • KeyBank National Association's Vertex Pharmaceuticals position peaked at $37.6M in Q2 2020.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on KeyBank National Association's 13F filing for Q2 2026, filed 28 Jul 2026.